Treatment of Cancer Pain by Targeting Cytokines

Vendrell, I.; Macedo, Daniela; Alho, Irina; Dionísio, Maria Rita; Costa, Luís

doi:10.1155/2015/984570

Cited by 43 publications

(31 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several mechanisms have been postulated to explain the mechanisms underlying the carboplatin -induced toxicities such as production of reactive oxygen species (ROS), nitric oxide (NO) [3] and proinflammatory cytokines e.g. interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα) [4].…”

Section: Introductionmentioning

confidence: 99%

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

Elgendy

Elsaed

Badawy

2019

BESPS

View full text Add to dashboard Cite

Carboplatin is a neoplastic agent causing hematotoxicity, erythropoietin (EPO) resistance, increase oxidative stress and pro-inflammatory cytokines. Our study investigated the role of erythropoietin, vitamin C and L-NAME in carboplatin-induced hematological and renal dysfunctions. Seventy rats divided into seven groups; control, Carboplatin (100 mg/kg.), Carboplatin (250 mg/kg), Carboplatin (100 mg/kg.) pretreated by EPO , Carboplatin (250 mg/kg) pretreated by EPO, Carboplatin (250 mg/kg) pretreated by EPO & Vitamin C and Carboplatin (250 mg/kg) pretreated by EPO & L-NAME. Hematological, plasma inflammatory cytokines, renal functions , oxidant, antioxidant parameters , serum EPO and vitamin C were measured with histopathology of renal tissue. Carboplatin decreased RBC count, hemoglobin concentration, packed cells volume, platelets count , superoxide dismutase , catalase and glutathione peroxidase, serum erythropoietin and vitamin C while WBCs count, interleukin 1, interleukin 6, tumor necrosis factor alpha, high-sensitivity C-reactive protein, serum blood urea nitrogen, serum creatinine, malondialdehyde and nitric oxide were increased. Vitamin C and L-NAME improved hematological derangement, EPO resistance, antioxidant parameters and histopathological findings while worsen plasma inflammatory markers, renal functions parameters and oxidative parameters. There was insignificant change in blood indices in all groups. We concluded that carboplatin had a hematological toxicity and oxidant stress effect in addition to increase proinflammatory cytokines and consequent renal insult. The development of EPO resistance was carboplatindose dependent. Vitamin C and L-NAME alleviate the hematological toxicity, oxidative stress, EPO resistance and decrease proinflammatory cytokines and in turn recovery of renal structure and functions.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

Elgendy

Elsaed

Badawy

2019

BESPS

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] Recent research has indicated that cytokines play a key role in mediating cancer pain. 8 Infiltrating pro-inflammatory immune cells found within tumors, as well as cancer cells themselves, release cytokines, which bind to and sensitize neighbouring nociceptors to painful stimuli and elicit a central pain response. 8 Cancer is a systemic inflammatory state, and many of the symptoms experienced by cancer patients, including pain, can be attributed to the action of cytokines on the peripheral and central nervous systems.…”

Section: Introductionmentioning

confidence: 99%

“…8 Infiltrating pro-inflammatory immune cells found within tumors, as well as cancer cells themselves, release cytokines, which bind to and sensitize neighbouring nociceptors to painful stimuli and elicit a central pain response. 8 Cancer is a systemic inflammatory state, and many of the symptoms experienced by cancer patients, including pain, can be attributed to the action of cytokines on the peripheral and central nervous systems. 9 In healthy individuals, pro-and anti-inflammatory cytokines exist in equilibrium which is disrupted in the development of cancer, with patients showing both immuno-stimulatory and immunosuppressive profiles.…”

Section: Introductionmentioning

confidence: 99%

<p>Applying Serum Cytokine Levels to Predict Pain Severity in Cancer Patients</p>

Fazzari

Sidhu

Motkur

et al. 2020

JPR

View full text Add to dashboard Cite

Background and Aim: Cancers originating in the breast, lung and prostate often metastasize to the bone, frequently resulting in cancer-induced bone pain that can be challenging to manage despite conventional analgesic therapy. This exploratory study's aim was to identify potential biomarkers associated with cancer-induced pain by examining a sample population of breast cancer patients undergoing bisphosphonate therapy. Methods: A secondary analysis of the primary study was performed to quantify serum cytokine levels for correlation to pain scores. Cytokines with statistically significant correlations were then input into a stepwise regression analysis to generate a predictive equation for a patient's pain severity. In an effort to find additional potential biomarkers, correlation analysis was performed between these factors and a more comprehensive panel of cytokines and chemokines from breast, lung, and prostate cancer patients. Results: Statistical analysis identified nine cytokines (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-12p70, IL-17A, and IL-23) that had significant negative correlations with pain scores and they could best predict pain severity through a predictive equation generated for this specific evaluation. After performing a correlation analysis between these factors and a larger panel of cytokines and chemokines, samples from breast, lung and prostate patients showed distinct correlation profiles, highlighting the clinical challenge of applying pain-associated cytokines related to more defined nociceptive states, such as arthritis, to a cancer pain state. Conclusion: Exploratory analyses such as the ones presented here will be a beneficial tool to expand insights into potential cancer-specific nociceptive mechanisms and to develop novel therapeutics.

show abstract

“…The breast cancer is the second leading cause of death in women (1). It is estimated that by 2020, 70 percent of new cases of breast cancer will be observed in developing countries (2). The International Association for the Study of Pain (IASP) reported that the prevalent of pain in breast cancer is between 40% to 89% (3) and 17 million people complain of cancer pain.…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of Acceptance and Commitment Therapy (ACT) on Reducing the Severity of Perceived Pain in Women with Breast Cancer

Mami

Tahmasebian

Jahangiri

2018

J Clin Res Paramed Sci

View full text Add to dashboard Cite

Background: Breast cancer is one of the most prevalent and painful cancers amongst women in the world. The purpose of this study was to investigate the effectiveness of acceptance and commitment therapy on reducing the severity of pain in women with breast cancer. Methods: This was a quasi-experimental study which was conducted on 30 women with breast cancer referring to Ilam Medical Center in 2018. Patients were randomly assigned into two groups of experimental and control groups. Participants in the pre-test stage completed the multivariate questionnaire for the West Haven-Yale. At the next stage, the experimental group participants were exposed to 8 sessions of acceptance and commitment therapy while the control group did not receive any special treatment. Both groups completed the same questionnaire again at the posttest stage. Results: In terms of severity pain, mean scores of the experimental and control groups at the pretest stage were 76.66 and 74.98, respectively. Meanwhile, mean scores of the mentioned groups at the posttest stage were 70.08 and 74.06. The mean score of the experimental group in the posttest phase was decreased after the intervention compared to the control group. Conclusions: The results of the study reveal that acceptance and commitment therapy is a suitable intervention model for reducing the severity of perceived pain in breast cancer patients.

show abstract

Treatment of Cancer Pain by Targeting Cytokines

Cited by 43 publications

References 81 publications

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

<p>Applying Serum Cytokine Levels to Predict Pain Severity in Cancer Patients</p>

The Effectiveness of Acceptance and Commitment Therapy (ACT) on Reducing the Severity of Perceived Pain in Women with Breast Cancer

Contact Info

Product

Resources

About